Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. monthly Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own0.59% Shs Outstand39.32M Perf Week-5.28%
Market Cap796.62M Forward P/E- EPS next Y-2.73 Insider Trans47.77% Shs Float39.12M Perf Month-15.76%
Income-19.20M PEG- EPS next Q-0.67 Inst Own47.40% Short Float3.20% Perf Quarter51.19%
Sales117.70M P/S6.77 EPS this Y79.40% Inst Trans62.85% Short Ratio1.14 Perf Half Y39.72%
Book/sh2.74 P/B7.39 EPS next Y7.10% ROA-10.80% Target Price37.00 Perf Year25.06%
Cash/sh3.33 P/C6.09 EPS next 5Y- ROE-50.20% 52W Range11.30 - 27.86 Perf YTD42.68%
Dividend- P/FCF- EPS past 5Y35.00% ROI-16.30% 52W High-27.28% Beta1.42
Dividend %- Quick Ratio3.10 Sales past 5Y57.70% Gross Margin87.10% 52W Low79.29% ATR0.91
Employees106 Current Ratio3.20 Sales Q/Q-31.60% Oper. Margin-11.50% RSI (14)41.90 Volatility3.21% 3.96%
OptionableYes Debt/Eq0.77 EPS Q/Q31.00% Profit Margin-16.30% Rel Volume0.38 Prev Close20.53
ShortableYes LT Debt/Eq0.72 EarningsAug 07 AMC Payout- Avg Volume1.10M Price20.26
Recom2.10 SMA20-10.10% SMA501.59% SMA20028.54% Volume415,648 Change-1.32%
Jul-11-17Reiterated Citigroup Buy $23 → $37
Jul-07-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jun-27-17Initiated Citigroup Buy $23
May-19-17Initiated Leerink Partners Outperform $5
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Aug-13-17 05:36AM  Edited Transcript of ARNA earnings conference call or presentation 7-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 02:03PM  The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July Motley Fool
Aug-08-17 10:30AM  Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected Zacks -9.03%
08:00AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Opko Health ACCESSWIRE
Aug-07-17 11:57PM  Arena Pharmaceuticals reports 2Q loss Associated Press
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results PR Newswire
06:50AM  Investor Network: Arena Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 09:53PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : August 4, 2017 Capital Cube
09:51AM  Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y Zacks
Aug-02-17 12:41PM  What's in Store for Arena (ARNA) this Earnings Season? Zacks
Jul-31-17 04:32PM  Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017 PR Newswire
08:30AM  Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jul-26-17 11:13AM  These 3 Stocks Have Jumped 60% in a Single Month Motley Fool
Jul-24-17 10:18AM  Top Ranked Momentum Stocks to Buy for July 24th Zacks
Jul-17-17 03:11PM  Arena Announces Secondary Stock Worth $150M (revised) Zacks
01:54PM  Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says TheStreet.com
Jul-14-17 09:11AM  Top Ranked Momentum Stocks to Buy for July 14th Zacks
08:38AM  Why Arena Pharmaceuticals (ARNA) Could Be Positioned for a Surge Zacks
Jul-12-17 10:13AM  Arena Announces Secondary Stock Offering of 150M Shares Zacks
09:30AM  E*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics highlighted as Zacks Bull and Bear of the Day Zacks
Jul-11-17 04:50PM  What Happened in the Stock Market Today Motley Fool +41.38%
04:31PM  Arena Pharma shares retreat slightly on secondary share offering MarketWatch
04:05PM  Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
03:47PM  Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today Zacks
02:03PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : July 11, 2017 Capital Cube
01:58PM  Top Biotech Manager Sells Arena Pharmaceuticals On Today's Big Gain Forbes
12:58PM  A Glimpse Into Two Climbing Biotechs: Arena Pharmaceuticals, Inc. (ARNA) and Ocular Therapeutix Inc (OCUL) SmarterAnalyst
10:51AM  Arena's Ralinepag Positive in Phase II PAH Study, Shares Up Zacks
10:50AM  Why Arena Pharmaceuticals Is Knocking It Out of the Park 24/7 Wall St.
10:42AM  Arena Pharma Soars On Lung Disease Drug Study Results Barrons.com
09:43AM  Why Arena Pharmaceuticals Stock Is Bolting Higher Today Motley Fool
09:14AM  Biotech jumps 41% on promising drug to treat rare lung disease CNBC
08:00AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW Pharmaceuticals Accesswire
07:51AM  3 Stocks to Watch on Tuesday: Snap Inc (SNAP), Barracuda Networks Inc (CUDA) and Arena Pharmaceuticals, Inc. (ARNA) InvestorPlace
Jul-10-17 05:25PM  After-hours buzz: CUDA, ARNA & more CNBC
04:23PM  Arena Pharmaceuticals stock skyrockets on positive hypertension-drug study MarketWatch
04:01PM  Arena's heart-lung drug meets main goal in mid-stage study Reuters
04:01PM  Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension PR Newswire
Jul-07-17 09:09AM  Arena Upgraded, Analyst Sees 44% Upside Benzinga +7.00%
Jul-06-17 10:33AM  The Surprising Catalyst That Sent Arena Pharmaceuticals, Inc. Soaring 27% in June Motley Fool
Jul-05-17 08:47AM  Are Options Traders Betting on a Big Move in Arena Pharmaceuticals (ARNA) Stock? Zacks
Jun-29-17 08:30AM  Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers PR Newswire
Jun-28-17 02:32PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : June 28, 2017 Capital Cube +8.54%
Jun-26-17 10:16AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
Jun-23-17 09:04AM  Better Know a Marijuana Stock: Arena Pharmaceuticals Motley Fool -8.09%
Jun-22-17 08:48AM  Why Arena Pharmaceuticals (ARNA) Could Be Positioned for a Surge Zacks
08:30AM  Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4% Zacks
Jun-16-17 03:23PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
08:36AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : June 16, 2017 Capital Cube
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Adamis Pharmaceuticals and Arena Pharmaceuticals Accesswire
Jun-15-17 08:30AM  Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference PR Newswire -6.67%
Jun-14-17 04:01PM  Arena Pharmaceuticals Announces Shareholders and Board of Directors Approve Reverse Stock Split PR Newswire
09:59AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors PR Newswire
07:02AM  Why Is Arena (ARNA) Up 15.1% Since the Last Earnings Report? Zacks
Jun-01-17 08:30AM  Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th PR Newswire +6.15%
May-26-17 08:27AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May 26, 2017 Capital Cube
May-24-17 10:38AM  5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio Zacks
May-23-17 08:09AM  2 Marijuana Stocks That Rocketed Higher by a Double-Digit Percentage Last Week Motley Fool
May-22-17 09:47AM  Can This Struggling Biotech Become the Next Great Marijuana Stock? Motley Fool
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics Accesswire
May-19-17 05:05PM  Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Today Motley Fool +15.65%
May-18-17 08:30AM  Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City PR Newswire
May-16-17 04:30PM  Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference PR Newswire
May-11-17 08:56AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 10:08AM  Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down Zacks -7.75%
May-09-17 05:12PM  Arena Pharmaceuticals reports 1Q loss Associated Press +5.74%
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results PR Newswire
01:15PM  Investor Network: Arena Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-04-17 10:32AM  Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? Zacks -6.02%
May-02-17 08:30AM  Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017 PR Newswire
Apr-21-17 04:01PM  Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-19-17 02:51PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : April 19, 2017 Capital Cube
09:37AM  Arena Pharma (ARNA) Down After Underwritten Public Offering Zacks
07:30AM  Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics Accesswire
02:57AM  Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report? Zacks
Apr-18-17 12:52PM  Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers TheStreet.com -13.51%
11:05AM  Why Arena Pharmaceuticals Stock Is Getting Hammered Today Motley Fool
10:35AM  Arena Pharmaceuticals Sinks After Announcing Secondary Offering 24/7 Wall St.
08:31AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : April 18, 2017 Capital Cube
Apr-17-17 10:15PM  Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
08:30AM  Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology PR Newswire
Apr-11-17 06:00AM  The State of Play in Axovant Sciences Investopedia
Apr-10-17 03:48PM  Why Arena Pharmaceuticals Stock Slimmed Down in March Motley Fool
Apr-07-17 03:50PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : April 7, 2017 Capital Cube
Apr-06-17 09:11AM  New Strong Sell Stocks for April 6th Zacks
Mar-28-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics Accesswire
08:07AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 28, 2017 Capital Cube
Mar-27-17 03:49PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th PR Newswire
Mar-20-17 09:01AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer PR Newswire
Mar-18-17 01:04PM  ARENA PHARMACEUTICALS INC Financials
Mar-17-17 10:05AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017
Mar-15-17 02:36PM  How to Trade Wednesday's Most Active Stocks: Lloyds, Arena Pharma, MSCI and More TheStreet.com +12.68%
01:28PM  Why Arena Pharmaceuticals Stock Is Surging Higher Today Motley Fool
12:10PM  Wednesdays Biggest Biopharma Movers 24/7 Wall St.
11:54AM  Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
09:32AM  Biotech Premarket Movers: Arena, Immunomedics, Aralez
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company's proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Munshi AmitPresident and CEOMay 12Buy1.1925,00029,75076,875May 15 08:04 AM
Munshi AmitPresident and CEOApr 26Buy1.4150,00070,50051,875Apr 27 08:06 AM